Pachmarhi Beckons Anew with ₹33.88 Crore Tourism Boost
BHOPAL, MADHYA PRADESH , INDIA, June 5, 2025 / EINPresswire.com / -- Nestled in the verdant Satpura ranges, Pachmarhi—Madhya Pradesh's iconic hill station—has embarked on a transformative journey. Under the visionary initiative 'Virasat Se Vikas' (From Heritage to Development), Chief Minister Dr. Mohan Yadav recently inaugurated and laid the foundation for tourism development projects worth ₹33.88 crore. These efforts reaffirm the state's commitment to eco-sensitive, heritage-led, and experience-rich tourism.
Speaking at the launch, Chief Minister Dr. Mohan Yadav said:
'Under the leadership of Hon'ble Prime Minister Shri Narendra Modi, Madhya Pradesh is steadily converting its legacy into a force for development. Pachmarhi, celebrated for its pristine natural beauty and historical significance, is being developed into a premier tourist destination by addressing infrastructure gaps and introducing world-class facilities.'
Echoing the vision, Mr. Sheo Shekhar Shukla, Principal Secretary – Tourism & Culture and Managing Director of the Madhya Pradesh Tourism Board, stated:
'Pachmarhi has always charmed visitors. With consistent infrastructure upgradation, we aim to make every experience here more comfortable, memorable, and meaningful.'
Upgrading Infrastructure While Preserving Nature
The initiative focuses on enhancing visitor facilities while maintaining the ecological integrity of the region. Major developments include:
• Safe Drinking Water at Dhoopgarh – A ₹60 lakh pipeline and pump house ensure clean water access at the state's highest peak.
• Pink Toilets at Key Tourist Sites – Dedicated women's facilities at Jatashankar and Pandav Caves, managed by self-help groups, promote hygiene and empower local communities.
• Revamped Jaystambh Pathway – A four-kilometre stone-paved walkway with ambient lighting and seating, developed at a cost of ₹10 crore.
• Beautification & Entrance Upgrade – The main entrance to Pachmarhi and Satpura Retreat are being enhanced with modern aesthetics and amenities.
• New Community Centre – A heritage-style multipurpose space for events and cultural conventions.
Sustainability at the Core
In sync with the 2025 World Environment Day theme, 'Beat Plastic Pollution,' Pachmarhi is moving towards becoming a polythene-free zone. A fully automated RO plant, established for ₹34 lakh, will supply tourists with clean water in reusable glass bottles—fostering sustainability without compromising on service.
Eco-tourism hotspots such as Bee Fall, Chauragarh, Reechgarh, and Foot Hill are also being upgraded with an investment of ₹2.13 crore. Handi Khoh, one of the region's top attractions, is being enhanced with ₹1.98 crore allocated for amphitheatres, ramps, shaded rest areas, parking, and scenic viewing decks.
Heritage Revival and Community-Based Tourism
Among the most anticipated projects is the restoration of the historic Hilltop Bungalow into a heritage homestay. With an investment of ₹6.70 crore, the revamped site will feature luxury rooms, a library, restaurant, swimming pool, and curated landscaping—blending colonial-era elegance with modern comfort.
In addition, a central nursery is being developed at Hotel Glen View to nurture native plant species and support the aesthetic upkeep of Pachmarhi's landscapes.
Boost for Wildlife Tourism
For nature lovers and wildlife enthusiasts, the addition of 11 Trex Cruiser safari vehicles marks a major upgrade. These nine-seater, tourism-operated vehicles offer immersive forest experiences across the Satpura region, enhancing accessibility and comfort for visitors.
With over 2.87 lakh tourists visiting Pachmarhi in 2024, these developments are expected to significantly boost footfall—while ensuring tourism remains environmentally responsible and community-driven.
Madhya Pradesh Tourism invites travellers to rediscover Pachmarhi—where rich heritage, natural splendour, and visionary development converge to offer an experience that is both timeless and transformative
CR
Madhya Pradesh Tourism Board
email us here
Visit us on social media:
YouTube
X
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
42 minutes ago
- New York Times
Explosion at Indian Pharmaceutical Factory Kills 36
At least 36 people were killed and another three dozen seriously injured, officials said Tuesday, after a large explosion at a pharmaceutical factory set off a fire in the southern Indian state of Telangana. A day after the explosion, which occurred on Monday, firefighters had quenched the fire and were sifting through the burned wreckage of the plant at an industrial park about 30 miles from the state capital, Hyderabad, according to G.V. Narayana Rao, the state's fire services director. Emergency workers toured a scene of twisted metal and charred concrete as excavators worked their way between heaping piles of wires, pipes and other debris. Many of the injured were hospitalized with burns or suffering from smoke inhalation, but Mr. Rao said the death toll was not expected to rise. India is the world's largest manufacturer of generic pharmaceuticals, and industrial accidents at drug factories are common. However, Mr. Rao said, the death toll from Monday's incident is the largest from a fire in the state in more than 25 years. The plant, in Sangareddy, is owned by Sigachi Industries. It was manufacturing microcrystalline cellulose, a substance used in the production of medical capsules. While it remains unclear what caused the fire, Mr. Rao said initial clues pointed to a pressure buildup in a dryer system that may have resulted in a 'dust explosion.' In an post on social media, Prime Minister Narendra Modi of India wrote he was 'anguished by the loss of lives' and pledged 200,000 rupees, about $2,335, through his National Relief Fund to each of the deceased victims' next of kin.
Forbes
an hour ago
- Forbes
Supersede Raises $10 Million As Hardware Regains Investor Favor
Workers are producing a batch of export chain parts at the production workshop of a transmission ... More materials company in Huzhou, China, on January 23, 2024. (Photo by Costfoto/NurPhoto via Getty Images) As global supply chains fragment under the strain of tariffs, climate shocks, and political uncertainty, a new generation of manufacturers is rejecting the old playbook of centralized scale and offshore sourcing. Instead, they're building leaner, circular, and regionally grounded operations, designing for resilience in a world where disruption is becoming the default. A High-Performance Alternative To Plywood Among them is Supersede, an Arizona-based startup that has just closed $10 million in seed funding to expand its decentralized manufacturing model. The company produces high-performance structural panels made entirely from recycled plastic, an alternative to marine-grade plywood that is waterproof, rot-proof, recyclable, and free of formaldehyde or other toxic binders. Designed for use in boats, RVs, modular housing, and outdoor construction, Supersede says its panels offer a solution to the escalating volatility and environmental impact of traditional wood-based products. 'We're not selling a green premium,' explained co-founder and chief executive Sean Petterson in an interview. 'We're offering a high-performance material that's competitively priced and built to navigate the kind of volatility that has become the norm.' This desire for stability is gaining urgency. In early 2025, the U.S. imposed new tariffs on Canadian lumber, pushing duties as high as 35%. Some manufacturers paused production or abandoned cross-border sourcing altogether so Supersede's domestically sourced, waste-derived panels offered a reliable, price-stable alternative in a market where certainty is now a competitive advantage. The funding round, which combined $5 million in convertible debt and $5 million in senior secured equipment financing, was backed by a major U.S. building products distributor, Closed Loop Partners, and several strategic angel investors focused on circular innovation. The capital will fund the development of a second U.S. facility, expected to triple production capacity and create more than 50 new jobs. It's a significant expansion at a time when many manufacturers are struggling with labor constraints and ongoing supply pressures. Circular Manufacturing Meets Investor Momentum Supersede's approach, reclaiming unrecyclable post-industrial plastic and turning it into durable structural products, demonstrates the growing appeal of circular, localized manufacturing. 'Our customers are tired of the unpredictability,' said Petterson. 'They don't want to be at the mercy of lumber futures or geopolitical headlines. They want reliability.' Supersede's model aligns with a growing interest from deep tech investors, who are looking beyond digital platforms to startups reshaping the physical world. The 2025 Deep Tech Opportunities Report, released this month by venture firm DCVC, outlines a decisive pivot away from software-only investments and toward startups focused on making the physical world more stable, scalable, and sustainable. The idea is that resilience, not just efficiency, should be a defining metric of industrial innovation and the report highlights opportunities in waste valorization, modular production, and climate-adapted infrastructure. Supersede's panels directly reflect that thinking. They are said to outperform traditional plywood and eliminate the need for sanding, sealing, or drying, streamlining production and reducing labor costs for manufacturers. Supersede also runs a buyback program to reclaim offcuts and used panels, creating a closed-loop system that aligns with growing demand for zero-waste construction inputs. 'We see opportunity for more efficient materials management in the built environment, a sector that often sees high rates of material loss to landfills, and now faces material shortages and delays,' said Kristin Taylor, Venture Partner at Closed Loop Partners. 'Supersede is using post-industrial feedstock that is otherwise unrecoverable in traditional recycling markets today. By turning this material into durable building products, Supersede is accelerating a more domestic, value-added, resilient circular economy.' Supersede is not alone. A wave of hardware startups is gaining traction by solving foundational problems in energy, materials, and infrastructure. Examples highlighted in the DCVC report include Verdox, developing low-energy carbon capture systems; Fervo Energy, advancing next-generation geothermal power; and Twelve, which transforms CO₂ into industrial chemicals, each representing a shift toward deep tech with real-world industrial impact. Also featured are Alta Resource Technologies, using computational biochemistry to extract critical minerals like neodymium and gallium from e-waste, and Tidal Metals, which is pioneering magnesium extraction from seawater through a novel vapor adsorption system. Like Supersede, these companies are reimagining how essential materials are sourced and produced, favoring circular models, domestic resilience, and scalable infrastructure over legacy global supply chains. And while Supersede's model is built on sustainability, it's performance rather than virtue signalling that drives market adoption. It's a mindset increasingly common among today's industrial innovators - solve the hard, physical problems and the market will follow. The Supersede model speaks directly to the needs of today's stakeholders. Policymakers want to rebuild domestic manufacturing capacity. Consumers increasingly expect sustainability as a baseline, not a bonus. And manufacturers want materials they can rely on. 'We're not just trying to make a better product,' Petterson explained. 'We're trying to build a better way to manufacture, leaner, closer to home, and less dependent on fragile infrastructure.' Instead of building one massive centralized plant, the company is rolling out a network of micro-factories. Located near waste streams and customer hubs, these small-footprint facilities are designed to hire locally, cut transportation emissions, and respond quickly to demand. In a world of fragile global infrastructure, Supersede's model favors modularity over scale and resilience over complexity. 'Ultimately, companies want materials that work,' said Petterson. 'Consumers want options they can feel good about. And policymakers want domestic resilience. We're trying to be where all three of those things meet.'
Yahoo
3 hours ago
- Yahoo
Biosimilars Market Size to Hit $76.2 Billion by 2030 - Driving Value-Based Care for Drugmakers, Regulators & Emerging Markets
CHICAGO and PUNE, India, July 1, 2025 /PRNewswire/ -- What's Fuelling the US$76.2 Billion Biosimilars Market? The Global Biosimilars Market size is projected to be valued at USD 27.20 billion in 2023 and reach USD 76.20 billion by 2030, growing at a CAGR of 15.9% according to a new report by The Research Insights. This growth is driven by several key factors, including a rising number of regulatory approvals and product launches, the patent expiries of major biologics, and the increasing prevalence of chronic diseases that require effective and affordable treatment options. The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the Biosimilars Market growth of 15.9% comprises a vast array of product, application and geography which are expected to register strength during the coming years. For More Information and To Stay Updated on The Latest Developments in The Global Biosimilars Market Size, Download FREE Sample Pages: Why Are Biosimilars Emerging as the Backbone of Affordable Biologic Therapies? According to an exhaustive report by The Research Insights, the Biosimilars Market is experiencing significant growth. The rapidly evolving global pharmaceutical industry is characterized by several unique and trending factors contributing to shaping the current landscape and competitive dynamics of the biosimilars market. The key factors include the increasing demand for affordable biologic therapies driven by the rising healthcare expenditures and the burgeoning prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes across the globe. The impending or already occurred patent expiries of several blockbuster biologics drugs have created a conducive environment for biosimilar manufacturers, opening the market to more competition and new entrants at an accelerated rate. Additionally, the establishment of supportive regulatory frameworks and streamlined approval pathways in key markets such as the United States, European Union, and emerging economies, is enabling the fast-paced development and acceptance of biosimilars. Furthermore, growing awareness, education, and positive experience among physicians and patients is also contributing to a greater acceptance and adoption of biosimilars by effectively reducing the resistance to switching from reference products. The enhanced technological advancements in biologic drug manufacturing and analytical characterization are also driving down the cost of production while maintaining the high quality of biosimilar products. Collaborative efforts and strategic partnerships among key players such as biopharma companies, Contract Development and Manufacturing Organizations (CDMOs), and supportive government initiatives to increase the access to affordable biologics are also playing a vital role in facilitating the growth of the biosimilars market. Some of the other trends observed in the biosimilars space, which are set to influence the competitive dynamics, include the incorporation of digital health platforms, personalized medicine, and the application of artificial intelligence in biosimilar development. What Role Do Patent Expirations and Budget Constraints Play in the Biosimilars Boom? The loss of patents and exclusivity rights of several key biologic drugs is a major driver of the biosimilars market. Many of the high-cost, blockbuster biologic drugs such as Humira (adalimumab), Remicade (infliximab), Herceptin (trastuzumab), Enbrel (etanercept), etc., have already lost their patents or are about to, which has paved the way for the entry of biosimilar versions in the market. As biologics are some of the highest spending drugs across the globe, and since many of these medications are used for the treatment of chronic and complex diseases, such as cancer, rheumatoid arthritis, inflammatory bowel disease, diabetes, etc., healthcare systems are actively looking for more cost-effective alternatives to the originator products. In addition, biosimilars help in reducing the costs of expensive biologics, which often represent a major share of national drug budgets, and insurers' spending. Biosimilars typically provide a cost-saving alternative at 15–30% less expensive than the originator biologic products, while also assuring similar safety and efficacy profiles as demonstrated in head-to-head trials. This increased price competition helps in reducing the financial burden of these specialty drugs on the national healthcare systems, the health insurers, and the patients and thus will encourage faster uptake and deeper market penetration. For Detailed Market Insights, Visit: How Are Chronic Disease Burdens and Biologic Demand Powering the Biosimilars Market?The surging global burden of chronic and lifestyle-related diseases, such as cancer, autoimmune disorders, and diabetes, has led to the high demand for biologic therapies and subsequently for their biosimilar versions as well. Biologics are fast becoming the standard of care for many diseases for which either the existing therapies are not very effective, or patients do not respond to them adequately. However, their high cost can be a major barrier to the use of these biologic therapies, especially in low- and middle-income countries. Biosimilars present an excellent opportunity to address this unmet need by improving access to lifesaving medicines at reduced prices. Given the demographic shift toward the older population and the concomitant increase in the incidence of chronic diseases around the world, the demand for biosimilars is expected to grow at a much faster pace, especially in oncology, endocrinology, and immunology therapeutic areas, in the coming years. This is also further corroborated by the fact that healthcare providers and policy decision-makers are looking for cheaper ways to manage therapies for long-term diseases. Are Governments and Payers Creating the Perfect Storm for Biosimilar Expansion? The establishment of streamlined and accelerated regulatory pathways for biosimilars in key global markets, such as the U.S. FDA's Biologics Price Competition and Innovation Act (BPCIA) and the EMA's well-defined and established biosimilar guidelines, have also been key factors propelling the growth of this space. The approval requirements for biosimilarity, interchangeability, labeling, and pharmacovigilance have been clearly defined by the respective regulatory authorities, which will in turn increase the confidence of physicians, pharmacists, and patients in using biosimilars. In addition, several countries and health insurance providers have introduced supportive policies and strategies to promote the use of biosimilars over biologic originators, such as substitution laws, tendering, and reimbursement policies. For instance, countries such as Germany, the UK, and Norway have witnessed a significant uptake in biosimilar products due to national incentive programs, recommendations for substitution, and mandatory switching policies. Such policy support not only helps lower the entry barriers for the manufacturers and increase the safety and efficacy of biosimilar products, but also builds greater market confidence, which will in turn provide a favourable environment for greater adoption of biosimilars. Stay Updated on The Latest Biosimilars Market Trends: Where Is Biosimilar Adoption Accelerating Fastest—and Why Now? North America has long held its ground as the dominant regional player in the global biosimilar market, accounting for 40.4% of the total revenue generated in this Pacific is anticipated to exhibit a Compound Annual Growth Rate (CAGR) of 18.4% during the forecast period. The presence of key players such as Dr. Reddy's Laboratories, Biocon, Pfizer Inc., and Celltrion, has significantly influenced the development and commercialization of biosimilars in the region. How Are Product, Application, and Regional Dynamics Shaping the Global Biosimilars Market Landscape? Based on Product, the biosimilars market is divided into, Recombinant Non-glycosylated Proteins, and Recombinant Glycosylated Proteins. The recombinant non-glycosylated proteins segment led in terms of revenue share, accounting for approximately 54.9%. Based on Application, the biosimilars market is divided into, Oncology, Blood Disorders, Growth Hormonal Deficiency, Rheumatoid Arthritis, Chronic and Autoimmune Disorders, and Others. The segment that accounts for the largest share in terms of revenue is the chronic and autoimmune disorders category, accounting for around 21.6% of the market's total. The Biosimilars Market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Purchase Premium Copy of Global Biosimilars Market Size and Growth Report (2023-2030) at: Which Companies Are Defining the Biosimilars Landscape—and What's Powering Their Momentum? The Global Biosimilars Market is characterized by the presence of several major players, including: Amgen Inc. F Hoffman-La Roche Ltd. Sandoz International GmbH Dr. Reddy's Laboratories Ltd. Teva Pharmaceutical Industries Ltd. Pfizer Inc. Samsung Biopis Biocon Viatris Inc. Celltrion Healthcare Co.,Ltd. AbbVie Inc. These companies are adopting strategies such as new product launches, joint ventures, and geographical expansion to maintain their competitive edge in the market. What's Driving Innovation in the Global Biosimilars Market Today? In April 2025, Sandoz entered into a collaboration with Shanghai Henlius Biotech to commercialize a biosimilar of ipilimumab, a leading oncology therapy to treat certain types of cancers like colorectal cancer, esophageal cancer, hepatocellular carcinoma, malignant pleural mesothelioma, melanoma, non-small cell lung cancer, and renal cell carcinoma. In April 2025, Biocon and Regeneron formed a license agreement to commercialize Yesafili (aflibercept-jbvf), an interchangeable biosimilar to aflibercept, in the US. In April 2025, Biocon Biologics received approval from the US FDA for Jobevne (bevacizumab-nwgd), a biosimilar of Bevacizumab for intravenous use to treat several different types of cancer. In March 2025, Celltrion launched ZYMFENTRA (infliximab-dyyb) across the US market to treat ulcerative colitis (UC) or Crohn's disease (CD). For Region-Specific Market Data, Check Out Brief Sample Pages: Frequently Asked Questions (FAQs): What is the forecasted market size of the Biosimilars Market in 2030?The forecasted market size of the Biosimilars Market is USD 76.20 billion in 2030. Who are the leading players in the Biosimilars Market?The key players in the Biosimilars Market include, Amgen Inc.; FHoffman-La Roche Ltd.; Sandoz International GmbH; Dr. Reddy's Laboratories; Teva Pharmaceutical Industries Ltd; Pfizer Inc.; Samsung Biopis; Biocon; Viatris Inc.; Celltrion Healthcare Co.,Ltd; and AbbVie Inc. What are the major drivers for the Biosimilars Market? Several key factors are propelling this growth, including the increasing number of biosimilar launches and approvals and rising global demand for affordable alternatives to expensive biologic therapies Which is the largest region during the forecasted period in the Biosimilars Market?The North America has long held its ground as the dominant regional player in the global biosimilar market, accounting for 40.4% of the total revenue generated in this space. Which is the largest segment, by product, during the forecasted period in the Biosimilars Market?The recombinant non-glycosylated proteins segment led in terms of revenue share, accounting for approximately 54.9%. Conclusion: The biosimilars market is undergoing a transformation driven by advancements in biotechnology, evolving regulatory landscapes, and expanding manufacturing capabilities. The increasing prevalence of chronic diseases and the rising economic burden on healthcare systems have heightened the demand for affordable and accessible biologic treatments. This demand is driving the accelerated adoption of biosimilars, which are recognized for their clinical efficacy, cost-effectiveness, and improved accessibility. Biosimilars are poised to play a crucial role in broadening patient access to life-saving biologic therapies, especially in oncology, immunology, and endocrinology. The continuous enhancements in analytical characterization, real-world evidence generation, and pharmacovigilance are building confidence in the safety and interchangeability of biosimilars. Strategic collaborations, streamlined regulatory pathways, and supportive policies are propelling market penetration. As the global healthcare landscape shifts towards value-based care, biosimilars are emerging as indispensable components of sustainable healthcare delivery and pharmaceutical innovation. We offer customized research solutions if the above study does not fully align with your specific requirements: The report from The Research Insights, therefore, provides several stakeholders— pharmaceutical companies, healthcare providers, regulatory agencies, patients, payers/insurance companies, and government health authorities—with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities. With projected growth to US$ 76.20 billion by 2030, the Global Biosimilars Market represents a significant opportunity for, contract manufacturing organizations (CMOs), biotechnology startups, academic research institutions, investment firms, and technology providers can position themselves for success in this dynamic and evolving market landscape. The Critical Questions to be Asking: Rather than "Should we pursue biosimilars?", the strategic questions to be asking are: Which therapeutic areas provide the quickest route to biosimilar profitability in the context of upcoming patent expirations? Where should we build or acquire manufacturing capabilities to scale and meet global demand for biosimilars? How can we position our company as a trusted brand in the biosimilar space in an increasingly price sensitive market? Who should we partner with to effectively manage regulatory complexity and speed to global market access? Why is now the time to invest in biosimilars in order to compete in the changing landscape of chronic disease care and value-based healthcare? Check out more related studies published by The Research Insights: Biosimilar Contract Manufacturing Market: The Global Biosimilar Contract Manufacturing Market is expected to reach at USD 25.73 billion by 2030, according to a new report by The Research Insights. It is projected to expand at a CAGR of 15.9% during the forecast period. The rising prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes has created a substantial demand for biosimilars, which offer comparable efficacy to their reference biologics while being more cost-effective. Biosimilar Monoclonal Antibodies Market: According to a report by The Research Insights, the growth of the global biosimilar monoclonal antibodies market is driven by several key factors, including the increasing number of monoclonal antibody patent expirations, ongoing innovations in mAb technology, growing demand for cost-effective therapies, and the rising prevalence of chronic and autoimmune diseases such as cancer and rheumatoid arthritis. Browse More related reports on Healthcare Industry Market Reports – About Us: The Research Insights provides thoroughly conducted research which is backed up by real-time statistics and data. Our experts are eager to help you with any information required under the sun. The key to our success is keeping abreast with the markets, industries, and ever-changing consumer trends that matter. Our market research professionals have in-depth knowledge and expertise across various domains that includes IT and Telecom, Emerging Technologies, Consumer Offerings, Manufacturing and Others. We are committed to reviewing the scope and procedure of the research studies that you select and provide you with an accurate guidance in order to assist you in taking the correct business decisions. Contact Us:If you have any queries about this report or if you would like further information, please contact us: Contact Person: Kaushik RoyE-mail: sales@ +1-312-313-8080Blog: Press Release: Latest News: | Logo: View original content: SOURCE The Research Insights
